Ana Ruigómez (Ana Ruigomez)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Atrial Fibrillation

Venous Thromboembolism

Oral Anticoagulants

Clinical Practice

Top Venues

Pharmacoepidemiology and drug safety

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez
Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. PloS one 19 (3) (2024)
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez
Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. PloS one 19 (3) (2024)
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez
Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. PloS one 19 (3) (2024)
Luis Alberto García-Rodríguez, Ana Ruigómez, Cristina Rebordosa, Annemarie Voss, Elisabeth Smits, Karin M A Swart, Yanina Balabanova, Kiliana Suzart-Woischnik, Gunnar Brobert, Ron M C Herings
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries. Expert opinion on drug safety (2023)
Ana Ruigómez, Gunnar Brobert, Pareen Vora, Luis Alberto García-Rodríguez
Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network. Pharmacoepidemiology and drug safety 30 (2) (2020)
Luis Alberto García-Rodríguez, Mari-Ann Wallander, Leif Friberg, Ana Ruigómez, Cristina Rebordosa, Irene D Bezemer, Ron M C Herings, Saad Shakir, Alison Evans, Miranda Davies, Kiliana Suzart-Woischnik, Pareen Vora, Yanina Balabanova, Montse Soriano Gabarró, Gunnar Brobert
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice. Expert opinion on drug safety 19 (11) (2020)
Jorge Enrique Machado-Alba, Andrés Gaviria-Mendoza, Manuel E Machado-Duque, Carlos Tovar-Yepes, Ana Ruigómez, Luis Alberto García-Rodríguez
Use of non-vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database. Pharmacoepidemiology and drug safety 30 (4) (2020)
Javier Damián, Roberto Pastor-Barriuso, Fernando José García-López, Ana Ruigómez, Pablo Martínez-Martín, Jesús de Pedro-Cuesta
Facility ownership and mortality among older adults residing in care homes. PloS one 14 (3) (2019)
Ana Ruigómez, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García-Rodríguez
Ascertainment and validation of major bleeding events in a primary care database. Pharmacoepidemiology and drug safety 28 (2) (2018)